Pancreatic cancer vaccine shows promise in first human trial

An experimental pancreatic cancer vaccine shows promise in its first human trial, generating an immune response in 90% of high-risk patients.

Family medicine physician Dr. Jessica Gray details a new experimental pancreatic cancer vaccine showing promise in its first human trial. The vaccine, targeting the KRAS mutation, generated an immune response in 90% of high-risk patients. Dr. Gray discusses the 5-7 year timeline for public availability and emphasizes why pancreatic cancer is so deadly, highlighting advances in cancer treatments.